Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, People's Republic of China.
School of Pharmacy, Dalian Medical University, Dalian 116044, People's Republic of China.
Drug Des Devel Ther. 2021 Jan 12;15:111-124. doi: 10.2147/DDDT.S286315. eCollection 2021.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death across the globe. Its repeated exacerbation will seriously worsen the quality of life, aggravate the patients' symptoms, and bring a heavy burden on the patients and the society. Understanding the current status of drug therapy and the role of pharmaceutical care is essential for the management of COPD. In addition to the drugs already on the market, recent clinical trials also show that emerging novel drugs for treating COPD are being developed to prevent the symptoms, reduce the frequency of acute exacerbation, and improve the quality of life. Recent progress in new drug research should lead to novel treatment options for COPD patients in future clinical practice. The pharmaceutical care has shown significantly favourable impacts on addressing drug-related problems, supporting its vital role in the management of COPD, especially when there are a wide range of therapeutic agents. This review not only provides an overview of current treatment strategies but also further underlines the importance of new drug development and pharmaceutical care for patients with COPD.
慢性阻塞性肺疾病(COPD)是全球第四大致死原因。其反复发作会严重降低生活质量,加重患者症状,给患者和社会带来沉重负担。了解 COPD 的药物治疗现状和药学服务的作用,对于 COPD 的管理至关重要。除了已经上市的药物外,最近的临床试验还表明,正在开发用于治疗 COPD 的新型药物,以预防症状、减少急性加重的频率并提高生活质量。新药研究的最新进展应该会为未来的临床实践中为 COPD 患者带来新的治疗选择。药学服务在解决药物相关问题方面表现出显著的优势,支持其在 COPD 管理中的重要作用,特别是在有多种治疗药物的情况下。本综述不仅概述了当前的治疗策略,还进一步强调了新药开发和药学服务对 COPD 患者的重要性。